CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
首页Home / 产品查询Product Search / 按品种找对照品By drug substance / 盐酸万古霉素Vancomycin Hydrochloride
Vancomycin Hydrochloride

盐酸万古霉素 杂质对照品Vancomycin Hydrochloride Impurities

EP21 个杂质条目21 impurity entries

本页汇总 盐酸万古霉素 的 21 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 21 impurity reference standards of Vancomycin Hydrochloride with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 盐酸万古霉素(Vancomycin Hydrochloride)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStability-indicating spectrofluorimetric method with enhanced sensitivity for determination of vancomycin hydrochloride in pharmaceuticals and spiked human plasma: Application to degradation kinetics
    Journal of food and drug analysis · 2018 · El-Din MKS et al.  ·  PMID 29567255  ·  DOI
  2. 杂质研究Impurity studiesSTABILITY-INDICATING HPLC METHOD FOR DETERMINATION OF VANCOMYCIN HYDROCHLORIDE IN THE PHARMACEUTICAL DOSAGE FORMS
    Acta poloniae pharmaceutica · 2017 · Serri A et al.  ·  PMID 29474763
  3. 杂质研究Impurity studiesAnalysis of the Stability of Compounded Vancomycin Hydrochloride Oral Solution: A Comparison Between Formulations Prepared Using a Commercial Product and Using the Pure Active Ingredient
    Cureus · 2025 · Arroyo-Solorzano JD et al.  ·  PMID 41084695  ·  DOI
  4. 分析方法Analytical MethodsA combined qualitative and quantitative method development and validation of vancomycin hydrochloride injection formulation by HPLC and UV involving quality by design
    Biomedical chromatography : BMC · 2023 · Sasikala L et al.  ·  PMID 36517962  ·  DOI
  5. 分析方法Analytical MethodsUtility of Silver-nanoparticles for Nano-fluorimetric Determination of Vancomycin Hydrochloride in Pharmaceutical Formulation and Biological Fluids: Greenness Assessment
    Journal of fluorescence · 2022 · Mohamed AR  ·  PMID 35751750  ·  DOI

盐酸万古霉素 —— 原料药与杂质对照品Vancomycin Hydrochloride — drug substance & impurities

共 21 个条目(含原料药本体)21 items incl. the drug substance
Vancomycin Hydrochloride structure
EP原料药 APIAPI
盐酸万古霉素Vancomycin Hydrochloride
Vancomycin Hydrochloride
CAS No.1404-93-9
Chemical FormulaC66H75Cl2N9O24·n(HCl)
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 1 Hydrochloride (Vancomycin Hydrochloride EP Impurity A Hydrochloride) structure
EPA
盐酸万古霉素杂质1盐酸盐 (盐酸万古霉素EP杂质A 盐酸盐)Vancomycin Hydrochloride Impurity 1 Hydrochloride (Vancomycin Hydrochloride EP Impurity A Hydrochloride)
Vancomycin Hydrochloride Impurity 1 Hydrochloride (Vancomycin Hydrochloride EP Impurity A Hydrochloride)
CAS No.213997-73-0
Chemical FormulaC65H73Cl2N9O24·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 1 (Vancomycin Hydrochloride EP Impurity A) structure
EPA
盐酸万古霉素杂质1 (盐酸万古霉素EP杂质A)Vancomycin Hydrochloride Impurity 1 (Vancomycin Hydrochloride EP Impurity A)
Vancomycin Hydrochloride Impurity 1 (Vancomycin Hydrochloride EP Impurity A)
CAS No.91700-98-0
Chemical FormulaC65H73Cl2N9O24
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 2 (Vancomycin Hydrochloride EP Impurity B) (Vancomycin CDP-1) structure
EPB
盐酸万古霉素杂质2 (盐酸万古霉素EP杂质B) (万古霉素CDP-1)Vancomycin Hydrochloride Impurity 2 (Vancomycin Hydrochloride EP Impurity B) (Vancomycin CDP-1)
Vancomycin Hydrochloride Impurity 2 (Vancomycin Hydrochloride EP Impurity B) (Vancomycin CDP-1)
CAS No.55598-85-1
Chemical FormulaC66H74Cl2N8O25
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 3 (Vancomycin Hydrochloride EP Impurity C) structure
EPC
盐酸万古霉素杂质3 (盐酸万古霉素EP杂质C)Vancomycin Hydrochloride Impurity 3 (Vancomycin Hydrochloride EP Impurity C)
Vancomycin Hydrochloride Impurity 3 (Vancomycin Hydrochloride EP Impurity C)
CAS No.82198-76-3
Chemical FormulaC53H52Cl2N8O17
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 4 (Vancomycin Hydrochloride EP Impurity D) structure
EPD
盐酸万古霉素杂质4 (盐酸万古霉素EP杂质D)Vancomycin Hydrochloride Impurity 4 (Vancomycin Hydrochloride EP Impurity D)
Vancomycin Hydrochloride Impurity 4 (Vancomycin Hydrochloride EP Impurity D)
CAS No.101485-50-1
Chemical FormulaC59H62Cl2N8O22
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 6 (Vancomycin Hydrochloride EP Impurity F) structure
EPF
盐酸万古霉素杂质6 (盐酸万古霉素EP杂质F)Vancomycin Hydrochloride Impurity 6 (Vancomycin Hydrochloride EP Impurity F)
Vancomycin Hydrochloride Impurity 6 (Vancomycin Hydrochloride EP Impurity F)
CAS No.2415254-43-0
Chemical FormulaC67H77Cl2N9O24
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 8 (Vancomycin Hydrochloride EP Impurity H) structure
EPH
盐酸万古霉素杂质8 (盐酸万古霉素EP杂质H)Vancomycin Hydrochloride Impurity 8 (Vancomycin Hydrochloride EP Impurity H)
Vancomycin Hydrochloride Impurity 8 (Vancomycin Hydrochloride EP Impurity H)
CAS No.357396-41-9
Chemical FormulaC66H76ClN9O24
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 10 (Vancomycin Hydrochloride EP Impurity J) structure
EPJ
盐酸万古霉素杂质10 (盐酸万古霉素EP杂质J)Vancomycin Hydrochloride Impurity 10 (Vancomycin Hydrochloride EP Impurity J)
Vancomycin Hydrochloride Impurity 10 (Vancomycin Hydrochloride EP Impurity J)
CAS No.2416251-24-4
Chemical FormulaC66H75Cl2N9O24
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 11 (Vancomycin Hydrochloride EP Impurity K) (N-Methyl Vancomycin B) structure
EPK
盐酸万古霉素杂质11 (盐酸万古霉素EP杂质K) (N-甲基万古霉素B)Vancomycin Hydrochloride Impurity 11 (Vancomycin Hydrochloride EP Impurity K) (N-Methyl Vancomycin B)
Vancomycin Hydrochloride Impurity 11 (Vancomycin Hydrochloride EP Impurity K) (N-Methyl Vancomycin B)
CAS No.99759-13-4
Chemical FormulaC67H77Cl2N9O24
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 12 (Vancomycin Hydrochloride EP Impurity L) structure
EPL
盐酸万古霉素杂质12 (盐酸万古霉素EP杂质L)Vancomycin Hydrochloride Impurity 12 (Vancomycin Hydrochloride EP Impurity L)
Vancomycin Hydrochloride Impurity 12 (Vancomycin Hydrochloride EP Impurity L)
CAS No.79517-31-0
Chemical FormulaC66H74Cl2N8O25
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydroiodide structure
—
氢碘酸万古霉素Vancomycin Hydroiodide
Vancomycin Hydroiodide
CAS No.1401240-12-7
Chemical FormulaC66H75Cl2N9O24·n(HI)
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin structure
—Peptide
万古霉素Vancomycin
Vancomycin
Glycopeptide: heptapeptide core cross-linked by multiple aromatic rings, with di-saccharide / amino-sugar modifications
CAS No.1404-90-6
Chemical FormulaC66H75Cl2N9O24
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 15 (Des-Oxy-(2) Vancomycin B) structure
15
盐酸万古霉素杂质15 (脱氧(2)万古霉素B)Vancomycin Hydrochloride Impurity 15 (Des-Oxy-(2) Vancomycin B)
Vancomycin Hydrochloride Impurity 15 (Des-Oxy-(2) Vancomycin B)
CAS No.1141925-31-6
Chemical FormulaC66H75Cl2N9O23
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 17 structure
17
盐酸万古霉素杂质17Vancomycin Hydrochloride Impurity 17
Vancomycin Hydrochloride Impurity 17
CAS No.197638-25-8
Chemical FormulaC66H75Cl2N9O24·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 18 structure
18
盐酸万古霉素杂质18Vancomycin Hydrochloride Impurity 18
Vancomycin Hydrochloride Impurity 18
CAS No.115236-65-2
Chemical FormulaC59H62Cl2N8O23
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 20  (Vancomycin B 26-Methyl Ester) structure
20
盐酸万古霉素杂质20 (万古霉素B 26-甲酯)Vancomycin Hydrochloride Impurity 20 (Vancomycin B 26-Methyl Ester)
Vancomycin Hydrochloride Impurity 20 (Vancomycin B 26-Methyl Ester)
CAS No.250273-66-6
Chemical FormulaC67H77Cl2N9O24
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 22 structure
22
盐酸万古霉素杂质22Vancomycin Hydrochloride Impurity 22
Vancomycin Hydrochloride Impurity 22
CAS No.98510-29-3
Chemical FormulaC66H76ClN9O24
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 24 (N-Nitroso Vancomycin) structure
24
盐酸万古霉素杂质24 (N-亚硝基万古霉素)Vancomycin Hydrochloride Impurity 24 (N-Nitroso Vancomycin)
Vancomycin Hydrochloride Impurity 24 (N-Nitroso Vancomycin)
CAS No.155386-25-7
Chemical FormulaC66H74Cl2N10O25
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 27 (Dehydroxyl-Vancomycin B) structure
27
盐酸万古霉素杂质27 (脱氢万古霉素B)Vancomycin Hydrochloride Impurity 27 (Dehydroxyl-Vancomycin B)
Vancomycin Hydrochloride Impurity 27 (Dehydroxyl-Vancomycin B)
CAS No.1378999-72-4
Chemical FormulaC66H75Cl2N9O23
Purity>95%询价On request
10mg25mg50mg100mg
Vancomycin Hydrochloride Impurity 28 (Balhimycin) structure
28
盐酸万古霉素杂质28 (巴尔赫霉素)Vancomycin Hydrochloride Impurity 28 (Balhimycin)
Vancomycin Hydrochloride Impurity 28 (Balhimycin)
CAS No.140932-79-2
Chemical FormulaC66H73Cl2N9O24
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

盐酸万古霉素 —— 研究文献与合成路线Vancomycin Hydrochloride — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 盐酸万古霉素 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Vancomycin Hydrochloride. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. STABILITY-INDICATING HPLC METHOD FOR DETERMINATION OF VANCOMYCIN HYDROCHLORIDE IN THE PHARMACEUTICAL DOSAGE FORMS
    Serri A, Moghimp HR, Mahboubi A, et al. · Acta poloniae pharmaceutica · 2017 · 被引 8cited 8
  2. A combined qualitative and quantitative method development and validation of vancomycin hydrochloride injection formulation by HPLC and UV involving quality by design
    Sasikala L, Koteswara Rao V, Katari NK, et al. · Biomedical chromatography : BMC · 2023 · 被引 1cited 1

合成与制备工艺专利Synthesis & process patents

  1. AMYCOLATOPSIS ORIENTALIS VARIANT AND PROCESS FOR PREPARATION OF VANCOMYCIN HYDROCHLORIDE
    KIM SANG YUN, KIM DO SUN, JUNG HYUNG MO, LEE JUNG KUL · 公开号 JP2008194027JP2008194027 · 2008
  2. Preparation of high-purity vancomycin hydrochloride
    XIAOYONG WANG, XINQIANG SUN · 公开号 CN101440127CN101440127 · 2009
  3. Mutant strain of Amycolatopsis orientalis and process for preparing vancomycin hydrochloride
    KIM SANG YONG, KIM DO SUN, JUNG HYUNG MOO, LEE JUNG KUL · 公开号 EP1959006EP1959006 · 2008
  4. MUTANT STRAIN OF AMYCOLAPTOSIS ORIENTALIS AND PROCESS FOR PREPARING VANCOMYCIN HYDROCHLORIDE
    KIM SANG YONG, KIM DO SUN, JUNG HYUNG MOO, LEE JUNG KUL · 公开号 KR20080075979KR20080075979 · 2008
  5. Mutant strain of Amycolatopsis orientalis and process for preparing vancomycin hydrochloride
    KIM SANG YOUNG, KIM DO SUN, JUNG HYUNG MOO, LEE JUNG KUL · 公开号 US2008193986US2008193986 · 2008

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

盐酸万古霉素 杂质谱研究要点Vancomycin Hydrochloride — impurity profiling notes

下面这些是拿到 盐酸万古霉素 的 21 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 21 impurity entries for Vancomycin Hydrochloride, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances